A PEGylated derivative of DSG
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

DSG-mPEG(2000)

Item No. 37800

Technical Information
Formal Name
α-[2,3-bis[(1-oxooctadecyl)oxy]propyl]-ω-methoxy-poly(oxy-1,2-ethanediyl)
CAS Number
308805-39-2
Synonyms
  • 1,2-Distearoyl-rac-glycero-3-methylpolyoxyethylene
Molecular Formula
(C2H4O)nC40H78O5
Formula Weight
Purity
≥95%
A solid
Chloroform: 30 mg/ml
SMILES
COCCOCC(COC(CCCCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCCCC)=O
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Lipid Nanoparticle Resource Center for Additional Tools & Resources
    EXPLORE NOW
    Product Description

    DSG-mPEG(2000) is a PEGylated derivative of 1,2-distearoyl-sn-glycerol (DSG; Item No. 15079).1 It has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs). LNPs containing DSG-mPEG(2000) and encapsulating a toll-like receptor 7 (TLR7) and TLR8 agonist and a peptide antigen each conjugated to poly(L-glutamic acid) (PGA) increase the activation of dendritic cells, macrophages, and B cells in the draining lymph node and dendritic cells and B cells in the spleen in mice compared to the non-LNP-encapsulated PGA-conjugated TLR7/8 agonist and peptide antigen.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Van Lysebetten, D., Malfanti, A., Deswarte, K., et alLipid-polyglutamate nanoparticle vaccine platform. ACS Appl. Mater. Interfaces 13(5), 6011-6022 (2021).